Ghana election, test of democratic reputation

ACCRA, Ghana (AP) — Voters in Ghana were selecting their next president and a 275-seat parliament in elections Friday, solidifying the West African nation‘s reputation as a beacon of democracy in the region.

Some 14 million people are expected to turn out. President John Dramani Mahama, in office for only five months, is running against seven contenders. A former vice president, Mahama became president in July after the unexpected death of former President John Atta Mills. The 54-year-old is also a former minister and parliamentarian and has written an acclaimed biography, “My First Coup d’Etat.”

His main challenger is Nana Akufo-Addo, a former foreign minister and the son of one of Ghana’s previous presidents. The contender lost the 2008 election to Mills by less than 1 percent. Both men are trying to make the case that they will use the nation’s newfound oil wealth to help the poor.

Ghana, a nation of 25 million, is one of the few established democracies in the region as well as the fastest-growing economy. But a deep divide still exists between those benefiting from the country’s oil, cocoa and mineral wealth and those left behind financially.

In an interview on the eve of the vote, Akufo-Addo told The Associated Press that the first thing he will do if elected is begin working on providing free high school education for all. “It’s a matter of great concern to me,” he said, adding that he plans to use the nation’s oil wealth to educate the population, industrialize the economy and create better jobs for Ghanaians.

Policy-oriented and intellectual, Akufo-Addo is favored by the young and urbanized voters. He was educated in England and comes from a privileged family. The ruling party has depicted him as elitist, which Akufo-Addo calls “a little PR construct.”

“The idea that merely because you are born into privilege that automatically means you are against the welfare of the ordinary people, that’s nonsense,” he said.

Ghana had one of the fastest growing economies in the world in 2011. Allegations of corruption against the ruling party are rife.

Akufo-Addo said that if elected, he would not be able to weed out corruption in the government overnight.

“It’s a long fight,” he said. “But we build the institutions that can fight it.”

He said that in 30 years in politics he has never been accused of corruption.

Many analysts believe Mahama and Akufo-Addo are neck-and-neck.

Results are expected to be announced by Sunday, but could be delayed. If no one wins an absolute majority, a second round of voting will be held on December 28.

All candidates have signed a peace pact and have promised to accept the results of Friday’s poll.

Ghana, a nation of 25 million, has previously held five transparent elections in a row. Nearby Mali, which was also considered a model democracy, was plunged into chaos this March following a military coup.

__

Associated Press writer Francis Kokutse contributed to this report from Accra, Ghana.

Africa News Headlines – Yahoo! News

Read More..

Firm says first BlackBerry 10 phone to debut in March, QWERTY phone won’t launch until June

Research In Motion (RIMM) is gearing up for a series of make-or-break releases that could be considered the most important device launches in the company’s history. Everything is riding on the success of the RIM’s BlackBerry 10 platform, which will be unveiled in its finished state on January 30th next year. RIM CEO Thorsten Heins is on record confirming that BlackBerry 10 will launch in the first quarter and company COO Kristian Tear previously stated new BlackBerry devices will be available “not too long after” the platform is unveiled late next month, but exact timing is still a mystery. According to Boston-based brokerage firm Detwiler Fenton, however, RIM’s first two BlackBerry 10 handsets won’t launch until March and June, respectively.

“RIM’s stock has been on a tear recently thanks to a number of upgrades and optimism surrounding its upcoming BB10 platform,” Detwiler analysts wrote in a note to clients picked up by Forbes. “However, as we dig a little deeper, there appears to be a few issues that could set up for some disappointing numbers in the 2013 first half.”

The firm goes on state that AT&T (T) and T-Mobile will launch the first BlackBerry 10 smartphone some time in March, while Verizon Wireless (VZ) and Sprint (S) are targeting May launches. Detwiler also states that the second BlackBerry 10 smartphone, which will feature a touchscreen and a full QWERTY keyboard, might not launch until June.

“Therefore, it is possible RIMM’s February quarter may only see a very small number of BB10 sales with the May quarter also coming in light due to limited QWERTY keyboard shipments and limited shipments to Sprint and Verizon,” the firm continued. “It’s our opinion RIM will ship approximately 400,000 BB10 units in the February quarter and 2.2 million to 2.5 million units in the May quarter. While this is clearly a North American / developed market view, we think this is the right way to look at the 2013 first half because the initial BB10 handsets are higher end and not targeted for emerging markets.”

When asked to comment on the Detwiler note, RIM spokesman Nick Manning reiterated the company’s earlier position. ”Details of the commercial availability for BlackBerry 10 will be announced at the global launch events on January 30,” Manning said in a comment provided to BGR via email. “Our executives have made it clear that the touch screen device will be available shortly after launch with the physical keyboard version to follow shortly after that.”

BGR’s own sources were not able to provide details regarding the exact timing of RIM’s upcoming launches, however we are hearing from reliable sources that RIM’s QWERTY-equipped BlackBerry 10 smartphone will launch well ahead of the June timeframe mentioned by Detwiler.

Get more from BGR.com: Follow us on Twitter, Facebook

Wireless News Headlines – Yahoo! News

Read More..

Jobless rate hits four-year low, but economists skeptical

As much as his fans scream and yell when he walks on water or levitates, most people have a pretty good idea that magician/illusionist Criss Angel is somehow tricking them and not actually defying the laws of physics.

In much the same why, when this morning's surprisingly strong jobs data came out, professional investors and economists alike knew immediately that something was up. In a month when one of the nation's most disruptive storms in recent history occurred, for the Bureau of Labor Statistics to report that Hurricane Sandy did not have an impact and the unemployment rate fell to a four-year low of 7.7% and 146,000 new jobs were created, that defies the laws of reason.

"It's a little hard to believe quite honestly," says Dan North, chief economist at Euler Hermes, in the attached video. "If there's any report that deserved caveats and conditions it's this one."

And he's not alone. Peter Kenny from Knight Capital calls the report a ''head scratcher'' in a note to clients today, saying he never looks a gift horse in the mouth, but just can't get comfortable with the numbers. And Andrew Wilkinson, chief economic strategist at Miller, Tabak & Co., who correctly called for a much stronger than expected number yesterday, is already expecting the 20,000 reduction in construction jobs to be short-lived, reminding clients that "we know what follows any disaster."

Related: Resist Urge to Panic on November Jobs Report Says Wilkinson

It's not like the markets weren't ready for a wild pitch, so to speak, of a jobs report. The Wall Street Journal went as far as calling it "the least important jobs report in five years" given the diffused post-election environment and the fact the Fed meets next week.

The reaction in financial markets so far has been modest, as investors are seeing right through the headline number and seized upon the fact that the labor force fell by 350,000 last month, while the participation rate also dipped to 63.6%.

"You saw the unemployment go down this month sharply, but probably for the wrong reason," North says, adding that the report is positive but still "way short of what we need to have for good growth."

With the jobs report now behind us, we begin to get set for the Fed's last meeting of the year, next Tuesday and Wednesday, with comparably low expectations, as economists like North, and presumably those that sit alongside Ben Bernanke at the central bank too, did not see this report as a game changer in any way.

What that means is that we can, as they say in the TV business, return to our regularly scheduled programming which means our singular focus on fiscal cliff resolutions can resume.

Read More..

“Dancing with the Stars” Burke says voice fine after thyroid surgery

LOS ANGELES (Reuters) – “Dancing with the Stars” co-host Brooke Burke said on Thursday that her surgery for thyroid cancer had gone well and that she had not lost her voice.

“Thank God it’s over. I’m clean, surgery went well & I can talk. Losing my voice was my biggest fear. Thx for all your prayers & light,” Burke said in a Twitter posting.

Burke, 41, a former winner of ABC-TV’s popular celebrity ballroom dancing competition, announced in November that she had been diagnosed with thyroid cancer.

The surgery took place just over a week after the season finale of “Dancing with the Stars” on November 27. The mother of four has said it will leave her with a large scar across her neck.

The thyroid is a gland in the neck that produces hormones that regulate vital body functions, such as heart rate and blood pressure.

(Reporting By Jill Serjeant; editing by Philip Barbara)

TV News Headlines – Yahoo! News

Read More..

Breast Cancer Vaccine a Reality for Women With HER-2 Negative Cancers

COMMENTARY | NeuVax, a breast cancer vaccine, is entering phase III trials. The drug’s manufacturer, Galena Biopharma, announced on Dec. 5, that it signed a distribution deal with TEVA Pharmaceuticals. TEVA will handle the global commercialization and distribution of the drug once it is out of trials. It is about time this is moving forward. We need to make progress toward ending this disease.

What is NeuVax?

A vaccine called NeuVax is close to being a reality for breast cancer patients. NeuVax is a vaccine, the first of its kind, to prevent breast cancer from recurring. A recurrence is when breast cancer returns to the same breast. If breast cancer appears in the other breast, it is not a recurrence but a new cancer.

Most women have a 15-20 percent chance of breast cancer recurring, even after a mastectomy. The implications of the vaccine are huge. It reduces the chance of breast cancer recurrence in women with node-positive, HER-2 negative breast cancers. About 75 percent of all breast cancer is HER-2 negative. The vaccine is given after the standard course of treatment is completed. It is not a replacement for radiation or chemotherapy. I would gladly try a vaccine over the currently available long-term recurrence preventions — all are hormone based and carry awful side effects.

Phase III trials

Unfortunately for me, there are no trials available in Arkansas. Even if there were, I am not eligible because my cancer is HER-2 positive, and I am thankfully, node-negative. This means that the cancer is not in my lymph system. Phase III trials are when the drug is actually tested in random settings on humans. This drug seems to be very promising. Right now, phase III trials are open in the United States and Canada. Israel will have at least four phase III trials opening soon. You can see if there are trials near you at the NeuVax website.

This vaccine has the potential to replace hormone therapies like tamoxifen and aromatase inhibitors. Both types of drugs have serious side effects. A vaccine, taken over the course of three years, reduces the time a patient needs to take medications and it helps to prevent recurrence. Hopefully the phase III trials go well and we get this vaccine available to breast cancer patients soon.

Lynda Altman was diagnosed with breast cancer in November 2011. She writes a series for Yahoo! Shine called “My Battle With Breast Cancer.”

Medications/Drugs News Headlines – Yahoo! News

Read More..

South Africa military plane crashes in mountains

JOHANNESBURG (AP) — A South African military aircraft on an unknown mission to an area near the village where former President Nelson Mandela lives crashed in a mountain range, officials said Thursday. It was unclear whether there were any survivors.

The Douglas DC-3 Dakota, a twin-propeller aircraft, had taken off from Pretoria’s Waterkloof Air Force Base on Wednesday night, said Brig. Gen. Xolani Mabanga, a military spokesman. On Thursday morning, soldiers found the wreckage of the airplane in the Drakensberg mountains near Ladysmith in KwaZulu-Natal province, some 340 kilometers (210 miles) southeast of the air base, Mabanga said.

Mabanga said soldiers had been sent to the scene to look for survivors. Mabanga said he did not know what the mission of the aircraft was, though it had planned to land in Mthatha in the country’s Eastern Cape. Siphiwe Dlamini, a Defense Ministry spokesman, declined to immediately comment Thursday morning.

Mthatha is about 30 kilometers (17 miles) north of Qunu, the village where Mandela now lives after retiring from public life. South Africa‘s military remains largely responsible for the former president’s medical care. However, military officials declined to say whether those on board had any part in caring for Mandela.

In November, another South African military flight crash landed at Mthatha, sending several people to the hospital with injuries. However, at that time, the military denied that those on board had anything to do with Mandela’s care.

Mandela, 94, was imprisoned for nearly three decades for his fight against apartheid before becoming the nation’s president in the country’s first fully democratic vote in 1994.

___

Jon Gambrell can be reached at www.twitter.com/jongambrellAP .

Africa News Headlines – Yahoo! News

Read More..

Apple to return some Mac production to U.S. in 2013: report

(Reuters) – Apple Inc is planning to bring back some of its production of Mac computers to the United States from China next year, Chief Executive Tim Cook said, according to a report published Thursday.

The company will spend more than $ 100 million to build the computers in the United States, Cook was cited as saying in an interview with Bloomberg Businessweek.

“This doesn’t mean that Apple will do it ourselves, but we’ll be working with people and we’ll be investing our money,” Cook said.

He told NBC in an interview to be aired late Thursday that only one of the existing Mac lines would be manufactured exclusively in the United States.

Higher-tech products are largely made overseas, often in subcontracted factories not owned by the brands whose products they are making.

Cheaper labor costs have been key in encouraging U.S. manufacturers to have move production to China, but with Chinese wage and transport costs increasing, the advantage against the U.S. has narrowed in recent years.

(Reporting by Nicola Leske; Editing by Bernadette Baum)

Tech News Headlines – Yahoo! News

Read More..

U.S. and Russia to meet on Syria amid chemical weapons fears

DUBLIN (AP) — The top U.S. and Russian diplomats will hold a surprise meeting Thursday with the United Nations' peace envoy for Syria, signaling fresh hopes of an international breakthrough to end the Arab country's 21-month civil war.

U.S. Secretary of State Hillary Rodham Clinton, Russian Foreign Minister Sergey Lavrov and mediator Lakhdar Brahimi will gather in Dublin on the sidelines of a human rights conference, a senior U.S. official said. The official spoke on condition of anonymity because she wasn't authorized to speak publicly on the matter. She provided few details about the unscheduled get-together.

Ahead of the three-way meeting, Clinton and Lavrov met separately Thursday for about 25 minutes. They agreed to hear Brahimi out on a path forward, a senior U.S. official said. The two also discussed issues ranging from Egypt to North Korea, as well as new congressional action aimed at Russian officials accused of complicity in the death of lawyer Sergei Magnitsky.

The former Cold War foes have fought bitterly over how to address Syria's conflict, with Washington harshly criticizing Moscow of shielding its Arab ally. The Russians respond by accusing the U.S. of meddling by demanding the downfall of President Bashar Assad's regime and ultimately seeking an armed intervention such as the one last year against the late Libyan strongman Moammar Gadhafi.

But the gathering of the three key international figures suggests possible compromise in the offing. At the least, it confirms what officials describe as an easing of some of the acrimony that has raged between Moscow and Washington over the future of an ethnically diverse nation whose stability is seen as critical given its geographic position in between powder kegs Iraq, Lebanon and Israel.

The threat of Syria's government using some of its vast stockpiles of chemical weapons is also adding urgency to diplomatic efforts. Western governments have cited the rising danger of such a scenario this week, and officials say Russia, too, shares great concern on this point.

On Thursday, Syria's Deputy Foreign Minister Faisal Mekdad accused the United States and Europe of using the issue of chemical weapons to justify a future military intervention against Syria. He warned that any such intervention would be "catastrophic."

In Ireland's capital, one idea that Brahimi could seek to resuscitate with U.S. and Russian support would be the political agreement strategy both countries agreed on in Geneva in June.

That plan demanded several steps by the Assad regime to de-escalate tensions and end the violence that activists say has killed more than 40,000 people since March 2011. It would then have required Syria's opposition and the regime to put forward candidates for a transitional government, with each side having the right to veto nominees proposed by the other.

If employed, the strategy would surely mean the end of more than four decades of an Assad family member at Syria's helm. The opposition has demanded Assad's departure and has rejected any talk of him staying in power. Yet it also would grant regime representatives the opportunity to block Sunni extremists and others in the opposition that they reject.

The transition plan never got off the ground this summer, partly because no pressure was applied to see it succeed by a deeply divided international community. Brahimi's predecessor, former U.N. Secretary-General Kofi Annan, who drafted the plan, then resigned his post in frustration.

The United States blamed the collapse on Russia for vetoing a third resolution at the U.N. Security Council that would have applied world sanctions against Assad's government for failing to live by the deal's provisions.

Russia insisted that the Americans unfairly sought Assad's departure as a precondition and worried about opening the door to military action, even as Washington offered to include language in any U.N. resolution that would have expressly forbade outside armed intervention.

Should a plan similar to that one be proposed, the Obama administration is likely to insist anew that it be internationally enforceable — a step Moscow may still be reluctant to commit to.

In any case, the U.S. insists the tide of the war is turning definitively against Assad.

On Wednesday, the administration said several countries in the Middle East and elsewhere have informally offered to grant asylum to Assad and his family if they leave Syria.

The comments came a day after the United States and its 27 NATO allies agreed to send Patriot missiles to Turkey's southern border with Syria. The deployment, expected within weeks, is meant solely as a defensive measure against the cross-border mortar rounds from Syria that have killed five Turks, but still bring the alliance to the brink of involvement in the civil war.

The United States is also preparing to designate Jabhat al-Nusra, a Syrian rebel group with alleged ties to al-Qaida, as a foreign terrorist organization in a step aimed at blunting the influence of extremists within the Syrian opposition, officials said Wednesday.

Word of the move came as the State Department announced Clinton will travel to the Mideast and North Africa next week for high-level meetings on the situation in Syria and broader counter-terrorism issues. She is likely then to recognize Syria's newly formed opposition coalition as the legitimate representative of the Syrian people, according to officials.

The political endorsement is designed to help unite the country against Assad and spur greater nonlethal and humanitarian assistance from the United States to the rebels.

Read More..

“Community”: Jason Alexander filming “Crazy” guest spot

LOS ANGELES (TheWrap.com) – “Community” might be losing a Chevy Chase, but it’s gaining a Jason Alexander.

Former “Seinfeld” star Alexander, who played neurotic bumbler George Costanza on the series, will guest-star on the beleaguered NBC comedy, and while the actor is tight-lipped on the details, he promises that the episode will be a doozy.

“Filming a crazy episode of ‘Community’ this week,” the actor tweeted early Tuesday. “Can’t say much about it but it’s a fun one.”

It is not known what role Alexander, who guest-starred on “Two and a Half Men” earlier this year, will play on the series, or if he will appear on more than one episode. A spokeswoman for the NBC series has not yet responded to TheWrap’s request for comment.

Last month, news broke that Chevy Chase – who plays Pierce Hawthorne on the series – is leaving “Community,” following an ugly standoff with the show’s creator and former showrunner, Dan Harmon, and an incident when he reportedly tossed out the N-word, after complaining about his character’s racism. Chase will appear in most of the episodes of the upcoming fourth season.

“Community” returns to the air February 7.

TV News Headlines – Yahoo! News

Read More..

Lundbeck anticipates new drug “feast”

LONDON (Reuters) – Danish group Lundbeck is looking forward to a “feast” of new drugs to refresh its product line-up, kicking off next week with a possible European Union green light for a novel medicine to treat alcohol abuse.

In all, there is scope for regulatory approval of three medicines in 2013 – an impressive tally for a small company focused on brain disorders – as well as a potential partnership deal for a drug to fight the symptoms of Alzheimer’s disease.

“Sometimes people say it is feast or famine for this industry and we are in a feast phase, especially considering our size,” chief executive Ulf Wiinberg told Reuters.

Lundbeck needs these new drugs to replace lost sales from antidepressant Cipralex, sold as Lexapro in the United States, which is now coming off patent.

Doubts about the company’s ability to make the transition from reliance on Cipralex has taken its toll on the stock in recent months, with the shares underperforming the European drugs sector by 23 percent this year.

There have even been suggestions the Lundbeck Foundation, which owns a 70 percent stake, might delist the drugmaker.

Wiinberg said this option had not be discussed. “If we were working on it I would say something, but I have nothing to say.”

While Wiinberg has already said earnings will stall until 2015 as a result of patent losses, he is increasingly confident the pieces are in place to lift sales in the medium term.

The next catalyst could come as early as December 13 or 14, when Lundbeck expects the European Medicines Agency to decide whether or not to recommend Selincro for alcohol dependence. A positive decision would lead to approval early next year.

The drug is breaking new ground in an uncertain market, and Wiinberg said it was “a bit of a joker in our portfolio”. Analysts currently pencil in only modest sales.

More important will be the verdict from regulators in North America and Europe later next year on a new antidepressant being developed with Japanese partner Takeda Pharmaceutical that analysts see as a potential $ 1-$ 2 billion-a-year seller.

Developing new treatments for depression has proved an uphill battle for drugmakers in recent times but vortioxetine has produced encouraging clinical trial results and its unique mode of action and flexible dosing could make it a winner.

The third approval prospect for next year is Abilify Maintena, a once-monthly version of schizophrenia drug Abilify that Lundbeck is working on with Otsuka.

Further out, Lundbeck is developing a drug for the symptoms of Alzheimer’s – a more modest ambition than that of disease-modifying treatments which have so far failed to gain much traction in tackling the underlying causes of the disorder.

That drug will be ready to go into final-stage clinical testing next year and Wiinberg said he would look to strike a partnership deal for the product, known as LuAE58054, at the same time as preparing for Phase III trials.

(Editing by Dan Lalor)

Medications/Drugs News Headlines – Yahoo! News

Read More..